BBIO BridgeBio Pharma, Inc.
Healthcare$67.73-2.01%ClosedMarket Cap: $13.27B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-5.93
P/S
23.34
EV/EBITDA
-26.69
DCF Value
$-135.93
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.8%
Operating Margin
-98.4%
Net Margin
-125.2%
ROE
36.0%
ROA
-52.9%
ROIC
-57.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $194.5M | 94.6% | $-106.0M | $-164.0M | $— | — |
| Q4 null | $154.2M | 90.0% | $-185.2M | $-197.2M | $— | — |
| FY null | $502.1M | 94.4% | $-569.1M | $-729.3M | $— | — |
| Q3 null | $120.7M | 94.6% | $-145.2M | $-182.7M | $— | — |
| Q2 null | $110.6M | 96.7% | $-134.3M | $-181.9M | $— | — |
| Q1 null | $116.6M | 97.7% | $-104.4M | $-167.4M | $— | — |
| Q4 null | $5.9M | 64.6% | $-226.0M | $-265.1M | $— | — |
| FY null | $221.9M | 98.3% | $-593.0M | $-535.8M | $— | — |
| Q3 null | $2.7M | 78.1% | $-191.8M | $-162.0M | $— | — |
| Q2 null | $2.2M | 72.4% | $-175.5M | $-73.5M | $— | — |
| Q1 null | $211.1M | 99.7% | $343.0K | $-35.2M | $— | — |
| Q4 2023 | $1.7M | 65.7% | $-177.4M | $-168.1M | $-0.96 | — |